Alprolix Market Report 2026

Alprolix Market Overview

• The Alprolix market growth in the historic period has been driven by high unmet need in hemophilia b management, limitations of plasma derived therapies • Market expansion is supported by rising hemophilia b patient population, increasing demand for long acting clotting factors • Growth Driver: Rising Hemophilia Cases To Propel Growth Of The Alprolix Market • Market Trend: Role Of Gene Therapies In Personalized Hemophilia B Care • North America was the largest region in 2025.

What Is Covered Under Alprolix Market?

Alprolix is a recombinant coagulation factor IX Fc fusion protein used to treat and prevent bleeding episodes in patients with hemophilia B. It functions by replacing the missing factor IX, enabling proper blood clotting, and features an extended half-life, reducing the frequency of infusions required for effective management. The main products of alprolix market are recombinant coagulation factor ix, and plasma-derived coagulation factor ix. Recombinant coagulation factor IX is a bioengineered protein used to replace the deficient or defective factor IX in patients with hemophilia B, facilitating proper blood clotting and preventing excessive bleeding. The various formulations include injectable solution and powder for reconstitution. These are used in various applications such as hemophilia b treatment, prophylaxis, and surgery and are distributed through various distribution channels such as hospitals, specialty clinics, and online pharmacies.

What Is The Alprolix Market Growth Forecast?

The alprolix market size is expected to see strong growth in the next few years. It will grow to $2.09 million in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to rising hemophilia b patient population, increasing demand for long acting clotting factors, improved access to specialty hemophilia care, expansion of home based infusion programs, continued innovation in factor fusion technologies. Major trends in the forecast period include growing adoption of extended half life factor ix therapies, increasing shift toward prophylactic hemophilia management, rising preference for reduced infusion frequency treatments, expansion of recombinant coagulation factor usage, improved patient adherence through long acting therapies.

Global Alprolix Market Segmentation

1) By Product: Recombinant Coagulation Factor IX, Plasma-Derived Coagulation Factor IX 2) By Formulation: Injectable Solution, Powder For Reconstitution 3) By Application: Hemophilia B Treatment, Prophylaxis, Surgery 4) By Distribution: Hospitals, Specialty Clinics, Online Pharmacies

What Is The Driver Of The Alprolix Market?

The increasing prevalence of hemophilia B is expected to propel the growth of the alprolix market going forward. Hemophilia B, also known as Christmas disease, is a rare, inherited bleeding disorder caused by a deficiency or absence of clotting factor IX. The increasing prevalence of hemophilia is due to improved diagnostic techniques, better awareness and reporting of the condition, advancements in healthcare systems enabling earlier detection, and the extended life expectancy of individuals with hemophilia due to enhanced treatment options. Alprolix, a long-acting recombinant clotting factor IX, is helpful for hemophilia B as it reduces the frequency of bleeding episodes and the need for infusions by providing extended protection through its prolonged half-life, thereby improving the quality of life for patients. For instance, in October 2025, according to the report published by World Federation of Hemophilia (WFH), a Canada-based non-profit organization, as of 2024, there were 271,918 identified patients with hemophilia worldwide, including 224,353 with Hemophilia A and 45,600 with Hemophilia B. Therefore, the increasing prevalence of hemophilia B drives the alprolix industry.

Key Players In The Global Alprolix Market

Major companies operating in the alprolix market are Sanofi

Global Alprolix Market Trends and Insights

The alprolix market has seen significant advancements in recent years, driven by the growing focus on innovative therapies to address unmet medical needs in hemophilia B treatment. Factor IX gene therapies deliver a functional copy of the FIX gene using adeno-associated virus (AAV) vectors, providing long-term clotting factor production, reducing bleeding episodes, and potentially offering a one-time treatment for hemophilia B. For instance, in April 2024, Pfizer Inc., a US-based pharmaceutical manufacturing company, received the U.S. FDA approval for Beqveztm (fidanacogene elaparvovec), a gene therapy designed to treat hemophilia B, which is a rare blood-clotting disorder. This approval marks a significant milestone in hemophilia treatment, offering a potential one-time therapy that could reduce or eliminate the need for routine clotting factor infusions. It delivers a functional copy of the recombinant clotting factor IX gene to patients, which can provide sustained levels of factor IX, helping to prevent bleeding episodes. This approval followed a strong clinical trial showing that the treatment provided durable efficacy with a favorable safety profile for patients with severe or moderately severe hemophilia B.

What Are Latest Mergers And Acquisitions In The Alprolix Market?

In August 2024, Bora Pharmaceuticals, a Taiwan-based pharmaceutical company, acquired Emergent BioSolutions for an undisclosed amount. With this acquisition, Bora Pharma aims to expand its capabilities in the biotechnology and pharmaceutical sectors, enhancing its contract development and manufacturing services (CDMO) portfolio. Emergent BioSolutions Inc. is a US-based company that offers recombinant coagulation factor IX-based drugs.

Regional Insights

North America was the largest region in the alprolix market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Alprolix Market?

The alprolix market consists of sales of alprolix 250IU and alprolix 500 IU. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Alprolix Market Report 2026?

The alprolix market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the alprolix industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.